Results 1 to 10 of about 630,325 (166)

Case Report: KLHL11 encephalitis in a female patient with dual primary malignancies of breast and lung cancer: response to FcRn inhibitor therapy [PDF]

Frontiers in Immunology
Kelch-like protein 11 (KLHL11) encephalitis is a rare clinical condition characterized by autoimmune-mediated encephalitis associated with the presence of KLHL11 antibodies, which commonly presents with ataxia, diplopia, vertigo, hearing loss, and ...
Yapeng Li, Yapeng Li, Haoran Xing, Zhentang Cao, Zhentang Cao, Pan Cui, Pan Cui, Lu Zhao, Lu Zhao   +8 more
doaj   +6 more sources

Clinical Significance of Serum Albumin and Implications of FcRn Inhibitor Treatment in IgG-Mediated Autoimmune Disorders [PDF]

Frontiers in Immunology, 2022
Serum albumin (SA), the most abundant soluble protein in the body, maintains plasma oncotic pressure and regulates the distribution of vascular fluid and has a range of other important functions.
E. Sally Ward, Deborah Gelinas, Erwin Dreesen, Jolien Van Santbergen, Jan Terje Andersen, Jan Terje Andersen, Nicholas J. Silvestri, Joseph E. Kiss, Darrell Sleep, Daniel J. Rader, John J. P. Kastelein, Els Louagie, Gestur Vidarsson, Gestur Vidarsson, Isabel Spriet, Isabel Spriet   +15 more
doaj   +4 more sources

Roles of FcRn in Antigen-Presenting Cells during Autoimmunity and a Clinical Evaluation of Efgartigimod as an FcRn Blocker

Pathogens, 2023
The immune system is a complex network of multiple cells, tissues, and organs that protects the body against foreign pathogenic invaders. However, the immune system may mistakenly attack healthy cells and tissues due to the cross-reactivity of anti ...
Yihan Zhou, Shisong Jiang
doaj   +4 more sources

Safety, tolerability, pharmacokinetics, and pharmacodynamics of HBM9161, a novel FcRn inhibitor, in a phase I study for healthy Chinese volunteers [PDF]

Clinical and Translational Science, 2021
Blockade of the binding between neonatal Fc receptor and IgG‐Fc reduces circulating IgG, and thus emerges as a potential therapy for IgG‐mediated autoimmune conditions.
Desmond Y. H. Yap, Jojo Hai, Paul C. H. Lee, Xueying Zhou, Michael Lee, Yu Zhang, Meng Wang, Xiaoxiang Chen   +7 more
doaj   +2 more sources

Comparing Efficacy and Safety of Various Monoclonal Antibodies in Myasthenia Gravis: A Systematic Review and Network Meta‐Analysis of Randomized Controlled Trials [PDF]

Brain and Behavior
Background Myasthenia gravis (MG) is an autoimmune disorder that causes muscle weakness due to disrupted neuromuscular transmission. This network meta‐analysis compared the safety and effectiveness of monoclonal antibodies used to treat MG.
Muhammad Hassan Waseem, Zain ul Abideen, Minahil Iqbal, Saniya Ishtiaq, Pawan Kumar Thada, Adam A. Dmytriw   +5 more
doaj   +2 more sources

The Comprehensive Live Cell-Based Cytotoxicity Assay for Monitoring Disease Activity and Guiding Rescue Therapy in Acute Attacks of NMOSD. [PDF]

Ann Clin Transl Neurol
ABSTRACT Objective Neuromyelitis optica spectrum disorder (NMOSD) is a devastating neurological disease that lacks serological biomarkers that can accurately reflect disease activity. We established a live cell‐based assay (LCBA) using serum with endogenous complement to quantify the overall cytotoxicity, offering a novel functional tool for monitoring
Xu X, Ding J, Du Y, Luo G, Li J, Liu R, Xu X, Li X, Li M, Jiang W, Yang C.   +10 more
europepmc   +2 more sources

FcRn antagonist and C5 complement inhibitor as early rescue strategies in severe Myasthenia Gravis: a two-case report [PDF]

Frontiers in Immunology
BackgroundMyasthenia gravis (MG) is an autoimmune neuromuscular disorder in which approximately 10–15% of patients with generalized AChR antibody–positive MG develop refractoriness to standard immunosuppressive therapies. Advanced therapeutic strategies,
Mosè Parisi, Mosè Parisi, Nicola Molitierno, Claudia Alberti, Delia Gagliardi, Daniele Velardo, Giacomo Pietro Comi, Giacomo Pietro Comi, Stefania Paola Corti, Stefania Paola Corti   +9 more
doaj   +2 more sources

Efgartigimod for generalized myasthenia gravis: a comprehensive review of clinical evidence and future perspectives [PDF]

Frontiers in Neurology
Efgartigimod, a first-in-class neonatal Fc receptor (FcRn) antagonist, has transformed the therapeutic landscape of generalized myasthenia gravis (gMG). This review synthesizes evidence from pivotal trials to real-world applications.
Lingyu Jiang, Jiaping Wei, Junqi Qin, Jing He, Shengjing Liang, Jianwei Huang, Yunzhi Ma, Yifan Zhou, Yonglong Zhong   +8 more
doaj   +2 more sources

Practical Guidance on Initiating and Switching Targeted Immunotherapies in Generalised Myasthenia Gravis: A German-Austrian Expert Opinion Paper. [PDF]

Eur J Neurol
ABSTRACT Background The therapeutic landscape of generalised myasthenia gravis (gMG) has evolved substantially with the approval of targeted immunotherapies, including complement C5 inhibitors (C5‐I) and neonatal Fc receptor inhibitors (FcRn‐I). While pivotal trials have demonstrated marked efficacy in defined subgroups, real‐world experience reveals ...
Meisel A, Marina AD, Doksani P, Hagenacker T, Kleinschnitz C, Krämer HH, Lünemann JD, Meuth SG, Ruck T, Schara-Schmidt U, Schneider-Gold C, Schoser B, Schroeter M, Schubert C, Sieb JP, Zimprich F, Zschüntzsch J, Hoffmann S.   +17 more
europepmc   +2 more sources

Proof-of-concept and Randomized, Placebo-controlled Trials of an FcRn Inhibitor, Batoclimab, for Thyroid Eye Disease

Journal of Clinical Endocrinology and Metabolism, 2023
Marius Stan, Sara Wester, Anja Eckstein   +2 more
exaly   +2 more sources